Search results for "ARDS"

showing 10 items of 1705 documents

Radiofrequency electromagnetic fields emitted from base stations of DECT cordless phones and the risk of glioma and meningioma (Interphone Study Grou…

2006

The objective of this study was to test the hypothesis that exposure to continuous low-level radiofrequency electromagnetic fields (RF EMFs) increases the risk of glioma and meningioma. Participants in a population-based case-control study in Germany on the risk of brain tumors in relation to cellular phone use were 747 incident brain tumor cases between the ages of 30 and 69 years and 1494 matched controls. The exposure measure of this analysis was the location of a base station of a DECT (Digital Enhanced Cordless Telecommunications) cordless phone close to the bed, which was used as a proxy for continuous low-level exposure to RF EMFs during the night. Estimated odds ratios were 0.82 (95…

AdultMaleNeoplasms Radiation-InducedPopulationBiophysicsRisk AssessmentMeningiomaBase stationElectromagnetic FieldsRisk FactorsGliomaGermanyCordless phoneMedicineHumansRadiology Nuclear Medicine and imagingeducationMicrowavesAgedProportional Hazards Modelseducation.field_of_studyRadiationbusiness.industryBrain NeoplasmsIncidenceDigital Enhanced Cordless TelecommunicationsEnvironmental ExposureGliomaMiddle Agedmedicine.diseaseCase-Control StudiesFemaleCell PhonesbusinessNuclear medicineMeningiomaCell Phone
researchProduct

Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

2017

<b><i>Background/Aim:</i></b> Individual components of the metabolic syndrome (MS) such as obesity or diabetes mellitus impair the prognosis of patients with hepatocellular carcinoma (HCC) following curative treatment approaches or transarterial therapies. The aim of this retrospective study was to assess the impact of these factors on the overall survival (OS) of patients with advanced HCC treated with sorafenib. <b><i>Methods:</i></b> Univariate and multivariate analyses were performed to assess the impact of individual components of the MS on the OS of 152 consecutive patients with advanced HCC treated with sorafenib. <b><i>Resu…

AdultMaleNiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsYoung Adult03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumansSurvival analysisAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overMetabolic Syndromebusiness.industryProportional hazards modelPhenylurea CompoundsLiver NeoplasmsHazard ratioGastroenterologyGeneral MedicineMiddle AgedSorafenibPrognosismedicine.diseaseSurvival Analysisdigestive system diseasesTreatment OutcomeDiabetes Mellitus Type 2030220 oncology & carcinogenesisHepatocellular carcinomaMultivariate AnalysisFemale030211 gastroenterology & hepatologyMetabolic syndromebusinessDyslipidemiamedicine.drugDigestive Diseases
researchProduct

Where is the limit of prostate cancer biomarker research? Systematic investigation of potential prognostic and diagnostic biomarkers

2019

Background The identification of appropriate biomarkers is essential to support important clinical decisions in patients with prostate cancer. The aim of our study was a systematic bioinformatical analysis of the mRNA expression of all genes available for the prostate adenocarcinoma cohort of The Cancer Genome Atlas (TCGA), regarding their potential prognostic and diagnostic role. Methods The study cohort comprises 499 patients (TCGA prostate cancer cohort). mRNA expression data were available for approx. 20,000 genes. The bioinformatical statistical pipeline addressed gene expression differences in tumor vs. benign prostate tissue (including gene set enrichment analysis, GSEA) in samples f…

AdultMaleOncologyBiochemical recurrencemedicine.medical_specialtyBiomedical ResearchMultivariate analysisBioinformaticsUrology030232 urology & nephrologyAdenocarcinomalcsh:RC870-923PrognosticCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineBiomarkers TumormedicineHumansDiagnosticEpigeneticsAgedProstate cancerProportional hazards modelbusiness.industryHazard ratiomRNA expressionProstatic NeoplasmsGeneral MedicineMiddle Agedlcsh:Diseases of the genitourinary system. UrologyPrognosismedicine.diseaseGene Expression Regulation NeoplasticReproductive Medicine030220 oncology & carcinogenesisCohortBiomarker (medicine)businessBiomarkersResearch ArticleBMC Urology
researchProduct

Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity

2006

This study tested the hypothesis that GLUT-1 is a marker of radioresistance in oral squamous cell carcinomas (OSCC). A GLUT-1 labeling index (LI) was determined by immunohistochemistry in 40 pretreatment OSCC biopsies. Radiation responses were categorized by histopathology of the resection specimens. Associations between the LI and radiation response, Kaplan-Meier survival estimates and Cox regression analysis for the variables GLUT-1, T-stage, N-stage and chemotherapy were examined. The median LI was 64.2% (range 14-100%). Tumors with65% of GLUT-1+cells were more resistant to radiation (p=0.023). Overall survival was higher (p=0.044) for subjects with low LI (median value) than those with …

AdultMaleOncologyendocrine systemCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentAntineoplastic AgentsRadiation ToleranceImmunoenzyme TechniquesRadioresistanceInternal medicineBiomarkers TumorHumansMedicineAgedRetrospective StudiesGlucose Transporter Type 1Chemotherapybusiness.industryProportional hazards modelHead and neck cancerMiddle AgedPrognosismedicine.diseaseCombined Modality TherapySurvival AnalysisNeoplasm ProteinsRadiation therapystomatognathic diseasesTreatment OutcomeOncologyEpidermoid carcinomaCarcinoma Squamous CellImmunohistochemistryFemaleMouth NeoplasmsHistopathologyOral Surgerybusinesshormones hormone substitutes and hormone antagonistsOral Oncology
researchProduct

Trends in Epidemiology, Treatment, and Survival of Hepatocellular Carcinoma Patients Between 1998 and 2009

2013

The aim of this study was to analyze clinical presentation, course of disease, and management of patients with hepatocellular carcinoma (HCC) in a German referral center between 1998 and 2009.HCC is a rare tumor in Germany, but its incidence has increased over the last 30 years. New therapies such as chemoembolization with drug-eluting beads, selective internal radiotherapy, and sorafenib were introduced recently; however, the impact on clinical management and overall survival (OS) is unclear.In this retrospective analysis, 1066 patients with HCC, separated into two 6-year periods (n=385; 1998 to 2003 and n=681; 2004 to 2009) were evaluated.The number of patients presenting each year (64 vs…

AdultMaleOncologymedicine.medical_specialtyCarcinoma HepatocellularTime FactorsAdolescentKaplan-Meier EstimateMedical OncologyRisk AssessmentArticleTertiary Care CentersGermanYoung AdultRisk FactorsGermanyInternal medicineEpidemiologymedicineCarcinomaHumansRegistriesYoung adultAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overbusiness.industryProportional hazards modelIncidence (epidemiology)Liver NeoplasmsAge FactorsGastroenterologyRetrospective cohort studyMiddle Agedmedicine.diseasedigestive system diseaseslanguage.human_languageTreatment OutcomeHepatocellular carcinomalanguageFemalebusinessJournal of Clinical Gastroenterology
researchProduct

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials

2005

Summary Background Chemotherapy is the standard treatment for advanced non-small-cell lung cancer, and myelosuppression is a common side-effect. We aimed to assess whether haematological toxic effects could be a biological measure of drug activity and a marker of efficacy. Methods We analysed data for 1265 patients who received chemotherapy (vinorelbine, gemcitabine, gemcitabine and vinorelbine, cisplatin and vinorelbine, or cisplatin and gemcitabine) within three randomised trials. Primary landmark analyses were restricted to 436 patients who received all six planned chemotherapy cycles and who were alive 180 days after randomisation. Neutropenia was categorised on the basis of worst WHO g…

AdultMaleOncologymedicine.medical_specialtyLung NeoplasmsNeutropeniamedicine.medical_treatmentAntineoplastic AgentsNeutropenia.VinorelbineSeverity of Illness IndexCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansLung cancerSurvival rateAgedProportional Hazards ModelsRandomized Controlled Trials as TopicAged 80 and overChemotherapyDose-Response Relationship Drugbusiness.industryStandard treatmentHazard ratioMiddle Agedrandomized clinical trialmedicine.diseaseGemcitabineSurgerySurvival Ratelandmark analysisnon-small-cell lung cancerItalyOncologychemotherapy-induced neutropeniaFemaleDrug MonitoringbusinessBiomarkersmedicine.drug
researchProduct

High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer

2020

Abstract Background The cell surface interleukin 22 (IL-22) receptor complex is mainly expressed in epithelial and tissue cells like pancreatitis cells. Recent studies described that IL-22R was overexpressed in malignant diseases and was associated with a poor overall survival (OS). The role of IL-22RA1 gene expression in muscle invasive bladder cancer (MIBC) has not been investigated, yet. Objectives The aim of this study was to analyze the role of IL-22RA1 gene expression in patients with MIBC. Methods In a cohort of 114 patients with MIBC who underwent radical cystectomy, IL-22RA1 gene expression was analyzed with qRT-PCR and correlated with clinical parameters. Furthermore, Kaplan-Meier…

AdultMaleOncologymedicine.medical_specialtyReceptor complexUrologymedicine.medical_treatment030232 urology & nephrologyCystectomyCohort StudiesCystectomyInterleukin 2203 medical and health sciences0302 clinical medicineInternal medicineGene expressionBiomarkers TumormedicineHumansNeoplasm InvasivenessAgedAged 80 and overMuscle NeoplasmsBladder cancerProportional hazards modelbusiness.industryReceptors InterleukinMiddle AgedPrognosismedicine.diseaseSurvival RateUrinary Bladder NeoplasmsOncology030220 oncology & carcinogenesisCohortT-stageFemalebusinessFollow-Up StudiesUrologic Oncology: Seminars and Original Investigations
researchProduct

Kappa free light chains in cerebrospinal fluid as markers of intrathecal immunoglobulin synthesis.

2004

Abstract Background: Intrathecal immunoglobulin synthesis is observed in several inflammatory disorders of the central nervous system, but its detection by current laboratory tests is either tedious or relatively insensitive. We assessed the diagnostic accuracy of an assay for κ free light chains (κFLC) in cerebrospinal fluid (CSF) and serum, and compared it with traditional tests for intrathecal immunoglobulin synthesis. Methods: κFLCs were measured by nephelometry in CSF/serum pairs from 112 patients. Samples were excluded if blood contamination of CSF as a result of traumatic lumbar puncture (n = 12) or monoclonal bands in both CSF and serum (n = 5) were present. The remaining sample pai…

AdultMalePathologymedicine.medical_specialtyMultiple SclerosisAdolescentClinical BiochemistryImmunoglobulin EImmunoglobulin light chainImmunoglobulin kappa-ChainsCerebrospinal fluidNephelometry and TurbidimetrymedicineHumansAgedAged 80 and overReceiver operating characteristicbiologybusiness.industryBiochemistry (medical)Oligoclonal BandsMiddle AgedReference StandardsROC CurveMonoclonalbiology.proteinFemaleAntibodybusinessNephelometryKappaBiomarkersClinical chemistry
researchProduct

Ophthalmic Outcomes of Congenital Toxoplasmosis Followed Until Adolescence

2014

BACKGROUND: Congenital toxoplasmosis (CT) can elicit severe damage to several organs, especially the eye, and may be manifested at birth or later. We assessed the long-term ocular prognosis in a cohort of congenitally infected children treated according to a standardized protocol and monitored for up to 22 years. METHODS: This prospective study included confirmed cases of CT, which were identified by obligatory antenatal screening at the Lyon (France) reference center between 1987 and 2008. Data obtained through ocular examinations were recorded on a standardized form and confirmed by an independent external committee. Risk factors for retinochoroiditis were identified by using a multivari…

AdultMalePediatricsmedicine.medical_specialtyAdolescentEye DiseasesToxoplasmosis CongenitalCohort StudiesLesionYoung AdultPregnancyHumansMedicineProspective StudiesChildProspective cohort studybusiness.industryProportional hazards modelChorioretinitisInfantmedicine.diseaseCongenital toxoplasmosisMaternal infectionTreatment OutcomeChild PreschoolPregnancy Complications ParasiticPediatrics Perinatology and Child HealthCohortOcular lesionFemaleFrancemedicine.symptombusinessFollow-Up StudiesPediatrics
researchProduct

Second Malignancies Following Childhood Cancer Treatment in Germany From 1980 to 2014.

2018

BACKGROUND Because of improvements in cancer treatment, more than 80% of all children with cancer now survive at least five years from the time of diagnosis. As a result, late sequelae of cancer and its treatment have become more common, particularly second malignancies. We studied the current incidence of second malignancies among childhood cancer survivors in Germany. METHODS This study is based on the cohort of the German Childhood Cancer Registry (Deutsches Kinderkrebsregister, DKKR). Persons given the diagnosis of a first malignancy at any time in the years 1980-2014 who were no more than 14 years old at the time of diagnosis and survived at least six months thereafter were included in…

AdultMalePediatricsmedicine.medical_specialtyPopulationMalignancy03 medical and health sciencesYoung Adult0302 clinical medicineCancer SurvivorsRisk FactorsGermanymedicineHumansCumulative incidence030212 general & internal medicineRegistrieseducationChildProportional Hazards Modelseducation.field_of_studyChildhood Cancer Registrybusiness.industryIncidence (epidemiology)IncidenceHazard ratioCancerNeoplasms Second PrimaryGeneral MedicineMiddle Agedmedicine.diseaseAdult Survivors of Child Adverse Events030220 oncology & carcinogenesisCohortFemaleOriginal ArticlebusinessDeutsches Arzteblatt international
researchProduct